drugset / Trial / NCT06681324

Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy

NCT06681324 ↗

Phase 2 Active not recruiting 24 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindOther

Summary

The purpose of this study is to evaluate safety, tolerability, and effect on mucosal repair of AZD7798 compared with placebo in participants with active ileal Crohn's disease and an ileostomy.

Timeline

Start
2024-12-11
Primary completion
2026-08-20
Completion
2027-09-03

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD7798 Unknown — —

Indications